Options: Show MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
| Indication | Labels | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
| Breast cancer stage IV | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
| Cardiotoxicity | x | ||||||||||||||||||||
| Colorectal cancer | x | x | x | x | x | x | x | x | x | x | x | ||||||||||
| Colorectal cancer metastatic | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
| Colorectal carcinoma | x | x | x | x | x | x | x | x | |||||||||||||
| Hyperbilirubinaemia | x | ||||||||||||||||||||
| Neoplasm | x | x | x | x | |||||||||||||||||
| Neoplasm malignant | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||
| Renal impairment | x | x | x | x | x | x | |||||||||||||||
standard – alternative
| 100% | ||
| 75% | ||
| 50% | ||
| 10% | ||
| frequent (1% to 100%) | ||
| infrequent (0.1% to 1%) | ||
| rare (<0.1%) | ||
| postmarketing | ||
| 0% | ||
| no frequency information | ||
| not found on label |